Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Vigolo S et al. Hematol Oncol Stem Cell Ther. 2017 Jun 15. pii: S1658-3876(17)30082-1. doi: 10.1016/j.hemonc.2017.05.027. [Epub ahead of print].
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.
Vogl DT et al. Leuk Lymphoma. 2017 Jun 22:1-8. doi: 10.1080/10428194.2017.1334125. [Epub ahead of print].
Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.
Huang SY et al. Hematol Oncol. 2017 Jun 19. doi: 10.1002/hon.2432. [Epub ahead of print].
UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy.
Douglas KW et al. J Clin Apher. 2017 Jun 20. doi: 10.1002/jca.21563. [Epub ahead of print].
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach.
Lanza F et al. Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24817. [Epub ahead of print].
Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.
Pavlů J et al. Bone Marrow Transplant. 2017 Jun 26. doi: 10.1038/bmt.2017.113. [Epub ahead of print].
Reduced intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Randall K et al. Eur J Haematol. 2017 Jun 20. doi: 10.1111/ejh.12917. [Epub ahead of print].
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Co-Morbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C et al. Biol Blood Marrow Transplant. 2017 Jun 8. pii: S1083-8791(17)30510-4. doi: 10.1016/j.bbmt.2017.06.001. [Epub ahead of print].
Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.
Iida S et al. Int J Hematol. 2017 Jun 22. doi: 10.1007/s12185-017-2281-6. [Epub ahead of print].
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A et al. Blood. 2017 Jun 21. pii: blood-2017-05-785246. doi: 10.1182/blood-2017-05-785246. [Epub ahead of print].
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG et al. Leukemia. 2017 Jun 2. doi: 10.1038/leu.2017.173. [Epub ahead of print].